1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Australian Stock Exchange  -  05/23 12:17:02 am EDT
0.3200 AUD   -3.03%
04/28HEXIMA : ShareCafe Presentation
PU
04/27HEXIMA : Notification regarding unquoted securities - HXL
PU
04/04HEXIMA : Investor Webinar on Today
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer

12/01/2021 | 04:38pm EDT

Hexima Limited announced the appointment of Dr Nancy Sacco, PhD as Chief Development Officer. Dr Sacco will report to Michael Aldridge, Managing Director & CEO. Prior to this appointment, Dr Sacco held Vice President and Head of Clinical Development roles at Xentria Inc. and AnaptysBio Inc., overseeing programs with monoclonal antibodies for rare and dermatologic diseases. In Dr Sacco's role at Hexima, she will be a senior U.S.-based Hexima representative and will lead the implementation of Hexima's development strategy and clinical development program. Dr Sacco will also be charged with representing the Company at FDA meetings and with other international regulators, and in interactions with scientific advisors, Key Opinion Leaders, and data review committee members.


© S&P Capital IQ 2021
All news about HEXIMA LIMITED
04/28HEXIMA : ShareCafe Presentation
PU
04/27HEXIMA : Notification regarding unquoted securities - HXL
PU
04/04HEXIMA : Investor Webinar on Today
PU
02/24HEXIMA : Application for quotation of securities - HXL
PU
02/23HEXIMA : Appendix 4D and Interim Financial Statements
PU
02/23Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2021
CI
02/08HEXIMA : Notification regarding unquoted securities - HXL
PU
01/31HEXIMA : Application for quotation of securities - HXL
PU
01/30HEXIMA : Quarterly Activities Report and Appendix 4C
PU
01/03Hexima Appoints Commercial Chief
MT
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,61 M -6,61 M
Net cash 2022 41,5 M 29,5 M 29,5 M
P/E ratio 2022 -5,49x
Yield 2022 -
Capitalization 53,5 M 38,0 M 38,0 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 47,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,32 AUD
Average target price 0,75 AUD
Spread / Average Target 134%
EPS Revisions
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-22.89%39
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567